GSK reveals data on novel gonorrhoea drug gepotidacin
GSK Posts Positive Phase III Gonorrhea Results for Antibiotic Gepotidacin
GSK has halted two phase 3 trials of its uncomplicated urinary tract infection (UTI) treatment early after the antibody hit its goals, teeing up the Big Pharma to submit the candidate for FDA approval next year.
Market Place
Share
Share
